TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma
A legfontosabb adatok
- Ki végzi
- Ascendis Pharma A/S
- Hol
- Boston, Canton, Charleston, Chicago, Cincinnati, Columbus, Detroit, Houston, Iowa City, Knoxville, Los Angeles, Louisville, New York, Rochester, San Francisco és Springfield (Egyesült Államok)Mind a 16 helyszín megnézéseMég 7 másik országban, 39 helyszínen
- Azonosító
- Állapot
- Leállítva
- Fázis
- 2. fázis
- Résztvevők
- 27 fő vett részt
- Kezdés
- 2023. szept. 29.
- Befejezés
- 2025. márc. 28.
- A vizsgálat típusa
- Beavatkozással járó, 3 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- TransCon TLR7/8 Agonist
- Pembrolizumab
- TransCon IL-2 β/γ
- A regiszteradat frissítve
- 2025. augusztus 1.
- Miért állt le
- The Sponsor made the decision to close enrollment as part of a strategic portfolio review.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 11 feltétel megnézéseKevesebb
Ki vehet részt
- Has local histologically confirmed new diagnosis of resectable, non-metastatic, SCC that is either: Stage III tumor HPV-positive oropharyngeal primary that is tumor size (T) 4, lymph node involvement (N) 0-2, no distant metastases (M) 0; Stage III or IVA oropharyngeal tumor HPV-negative; or Stage III or IVA larynx/hypopharynx/oral cavity primaries regardless of HPV status (per American Joint Committee on Cancer [AJCC] Staging, 8th edition)
- Has available archived or fresh core or excisional biopsy of a tumor lesion. Note: Fine needle aspirations may be allowed after discussion with Medical Monitor
- Is eligible and plans for primary LA-HNSCC surgery based on investigator decision and per local practice
- Has results from tumor HPV status by p16 immunohistochemistry (IHC) for oropharyngeal tumors. (HPV DNA analysis for HPV tumor status is acceptable if that is the local standard of care analysis.)
- Has adequate organ function at screening
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Has at least one lesion that is deemed by the investigator to be easily and safely accessible for IT injection
Ki nem vehet részt
- Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (in doses exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to randomization
- Active autoimmune conditions
- Has significant cardiac disease
- Has a known bleeding disorder that is deemed to place the participant at unacceptable risk for bleeding complications from IT injections or biopsies
Helyszínek itt: Egyesült Államok
Még 7 másik országban, 39 helyszínen
- Boston, MassachusettsHospital not named in the registry
- Canton, OhioHospital not named in the registry
- Charleston, South CarolinaHospital not named in the registry
- Chicago, IllinoisHospital not named in the registry
- Cincinnati, OhioHospital not named in the registry
- Columbus, OhioHospital not named in the registry
- Detroit, MichiganHospital not named in the registry
- Houston, TexasHospital not named in the registry
- Iowa City, IowaHospital not named in the registry
- Knoxville, TennesseeHospital not named in the registry
- Los Angeles, CaliforniaHospital not named in the registry
- Louisville, KentuckyHospital not named in the registry
- New YorkHospital not named in the registry
- Rochester, MinnesotaHospital not named in the registry
- San Francisco, CaliforniaHospital not named in the registry
- Springfield, IllinoisHospital not named in the registry
A vizsgálatról
Mit akar kideríteni a vizsgálat
The purpose of this trial is to evaluate the safety and efficacy of TransCon TLR7/8 Agonist, TransCon IL-2 β/γ, and pembrolizumab given prior to curative intent surgery in treatment of participants with newly diagnosed Stage III/IVA resectable locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC). After surgery, participants will receive local standard-of-care treatment and will be followed for safety, efficacy, and survival for up to 2 years.
A teljes eredeti leírásKevesebb
This trial contains a safety run-in to evaluate the safety and tolerability of the two treatment arms: Arm A (TransCon TLR7/8 Agonist plus pembrolizumab) and Arm B (TransCon TLR7/8 Agonist plus TransCon IL-2 β/γ). The safety run-in will be followed by the randomized Phase 2, open-label part of the trial comparing the safety, efficacy and survival of treatment Arm A or Arm B compared to treatment Arm C (pembrolizumab monotherapy).
A vizsgálat 3 csoportja
- TransCon TLR7/8 Agonist in combination with pembrolizumabA vizsgált kezelés
Participants receive 2 cycles, once every 3 weeks of TransCon TLR7/8 Agonist intratumoral (IT) injection in combination with pembrolizumab as a 30-minute intravenous (IV) infusion
Kezelés: TransCon TLR7/8 Agonist és Pembrolizumab
- TransCon TLR7/8 Agonist in combination with TransCon IL-2 β/γA vizsgált kezelés
Participants receive 2 cycles, once every 3 weeks of TransCon TLR7/8 Agonist (IT injection) in combination with TransCon IL-2 β/γ as a 30-minute IV infusion
Kezelés: TransCon TLR7/8 Agonist és TransCon IL-2 β/γ
- PembrolizumabMár használt kezelés, összehasonlításként
Participants receive 2 cycles, once every 3 weeks of pembrolizumab alone as a 30-minute IV infusion
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- BelieveIT-201: Phase 2, Randomized Open-labeled Trial of TransCon (TC) TLR7/8 Agonist in Combination With Pembrolizumab or With TC IL-2 β/γ, or Pembrolizumab Alone as Neoadjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma
- A regiszteradat frissítve
- 2025. augusztus 1.